Inactive Instrument

Cascadian Therapeutics Inc (USA) Stock Nasdaq

Equities

Duration

Period

Style

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress	18-01-04	GL
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency	18-01-02	GL
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index	17-12-13	GL
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer	17-12-07	GL
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results	17-11-08	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.85%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.42%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B